Abcam Honoured As One Of The UK’s Best Places To Work In 2020; A Glassdoor Employees’ Choice Award Winner

Cambridge UK, 11 December 2019: Abcam has been honoured with a Glassdoor Employees’ Choice Award, recognising the Best Places to Work in 2020. Abcam is ranked 6th in Glassdoor’s Best Places to Work UK list.

The Employees’ Choice Awards are based solely on the input of employees who elect to provide feedback on their jobs, work environments and companies on Glassdoor, one of the world’s largest job and recruiting sites.

Alan Hirzel, CEO, Abcam, commented “I’m delighted that our people have rated Abcam as one of the best places to work. As we continue to grow, we want to attract and retain the best talent to help us support the life science community in furthering their research. This phenomenal feedback demonstrates just how good a company we are to work for.”

Nick Skinner, SVP of Human Resources, Abcam said “We now have 450 colleagues working together in our new state of the art headquarters on the Cambridge Biomedical Campus. I am proud that we have a culture in which our employees can grow and thrive and develop their careers as we grow as an organisation. Thank you to all our employees who help to make us one of the best places to work.”

Christian Sutherland-Wong, Glassdoor President, Chief Operating Officer and incoming CEO said “This year marks the shift to a culture-first decade in the workplace. Glassdoor’s Employees’ Choice Awards winners are prioritising their culture and mission and putting employees at the heart of everything they do. In turn, their employees have recognised them as truly the Best Places to Work in 2020. In addition, this year’s winners stand out for providing exceptional career growth opportunities and encouraging work which is driven by impact and purpose. Congratulations go to all of the companies this year who stand out in the eyes of their employees.”


About Abcam

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.

Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company’s pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.

With ten sites globally, many of Abcam’s 1,100 strong team are located in the world's leading life science research hubs, complementing a global network of services and support.  Abcam was admitted to AIM in 2005 (AIM: ABC).

To discover more, please visit www.abcam.com and www.abcamplc.com.

Media Contact Information: 

Claire Thompson, claire.thompson@agilityhealthtech.com, M: 44 (0)7885591187